<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02804373</url>
  </required_header>
  <id_info>
    <org_study_id>13 6872 03</org_study_id>
    <nct_id>NCT02804373</nct_id>
  </id_info>
  <brief_title>Effects of Intranasal Administration of Oxytocin in Adults With Prader-Willi Syndrome</brief_title>
  <acronym>PRADOTIM</acronym>
  <official_title>Effects of Intranasal Administration of Oxytocin in Adults With Prader-Willi Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Toulouse</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Toulouse</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigator thinks that the oxytocin (OT) can improve durably and significantly the&#xD;
      behavior disorders and thus the socialization but also the satisfaction and could thus be an&#xD;
      interesting therapeutic alternative for the patients presenting a Prader-Willi Syndrome&#xD;
      (SPW). Although today several studies demonstrated the effects of the OT in various domains&#xD;
      of the behavior, the investigator do not know either its specificity of action about the&#xD;
      cerebral level, or its duration of action, or the optimal modalities of administration and in&#xD;
      particular at patients SPW.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 2014</start_date>
  <completion_date type="Actual">June 18, 2019</completion_date>
  <primary_completion_date type="Actual">January 2019</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Behaviour as assessed by score variations in specific questionaries</measure>
    <time_frame>Every day before and after administration of treatment during 28 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in eating Behaviour as assessed by score variations in specific questionaries</measure>
    <time_frame>Every day before and after administration of treatment during 28 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in eating behaviour as assessed by score variations in hunger visual analogic scale</measure>
    <time_frame>Every day before and after administration of treatment during 28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cerebral Metabolism variations as assessed by Positron Emission Tomography (PET-scan)</measure>
    <time_frame>Day 1, day 2 and day 30</time_frame>
    <description>Brain imaging</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cerebral Metabolism variations as assessed by functional Magnetic Resonance Imaging (f-RMI)</measure>
    <time_frame>Day 1, day 2 and day 29</time_frame>
    <description>Brain imaging</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of social skills assessed by specific questionnaires</measure>
    <time_frame>Day 1, day 2 and day 30</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of executive function assessed by specific questionnaires</measure>
    <time_frame>Day 1, day 2 and day 30</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of theory of mind assessed by specific questionnaires</measure>
    <time_frame>Day 1, day 2 and day 30</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Social processing assessed by oculomotor exploration</measure>
    <time_frame>Day 1, day 2 and day 30</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Multisensory processing assessed by Neurovisual task</measure>
    <time_frame>Day 1, day 2 and day 30</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hormon blood concentration levels as assessed by bioassays</measure>
    <time_frame>Day 2 and day 30</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Prader-Willi Syndrome</condition>
  <arm_group>
    <arm_group_label>placebo daily</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>daily administration of placebo during 28 days : placebo continuous</description>
  </arm_group>
  <arm_group>
    <arm_group_label>24 IU of oxytocin daily</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>24 IU of daily oxytocin administration during 28 days : oxytocin continuous</description>
  </arm_group>
  <arm_group>
    <arm_group_label>24 IU of oxytocin every 3 days</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>24 IU of daily oxytocin every 3 days and placebo the following 2 days after each oxytocin administration during 28 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxytocin (OXT) continuous</intervention_name>
    <description>Administration of 24 IU of oxytocin daily during 28 days</description>
    <arm_group_label>24 IU of oxytocin daily</arm_group_label>
    <other_name>Syntocinon</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo daily during 28 days</description>
    <arm_group_label>24 IU of oxytocin every 3 days</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo continuous</intervention_name>
    <description>Placebo administration the following 2 days after each OXT administration, during 28 days.</description>
    <arm_group_label>placebo daily</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxytocin</intervention_name>
    <description>Administration of 24 IU of oxytocin every 3 days during 28 days.</description>
    <arm_group_label>24 IU of oxytocin every 3 days</arm_group_label>
    <other_name>Syntocinon</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Prader-Willi syndrome genetically confirmed&#xD;
&#xD;
          -  Absence of extension of the QT interval in the electrocardiogram&#xD;
&#xD;
          -  Absence of hypokalemia&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Psychiatric troubles&#xD;
&#xD;
          -  Anomalies of the heart rhythm in significant ECG&#xD;
&#xD;
          -  Hepatic insufficiency&#xD;
&#xD;
          -  Renal insufficiency&#xD;
&#xD;
          -  Patients presenting a pregnancy or breast-feeding&#xD;
&#xD;
          -  High sensibility to OT&#xD;
&#xD;
          -  High sensibility to the excipients of the product&#xD;
&#xD;
          -  Patients having family history of genetic pathology causing an extension of the&#xD;
             interval QT&#xD;
&#xD;
          -  Patients having risk factors of advanced twist&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Maithé TAUBER, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Toulouse</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centre de référence Prader-Willi - Hôpital Purpan</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>July 10, 2015</study_first_submitted>
  <study_first_submitted_qc>June 14, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 17, 2016</study_first_posted>
  <last_update_submitted>July 31, 2020</last_update_submitted>
  <last_update_submitted_qc>July 31, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 3, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>oxytocin</keyword>
  <keyword>adults</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prader-Willi Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oxytocin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

